Why Globus Medical, Inc. (GMED) Stock Fell 12.8% on Nov 6, 2026
What happened
Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). The selloff was compounded by a 25.7% drop in Nevro sales, slower sales rep productivity, and delayed spine product launches now pushed to 2027, plus BMO Capital Markets downgrading GMED from Outperform to Market Perform with a price target cut from $94 to $78. Stock fell 11.15% to $72.36 on elevated volume of 5.1 million shares (6.08x historical average for this time of session).
Q4 2026 results and updated 2027 guidance (consensus EPS $1.33 expected at next earnings, scheduled for 2027-02-23); Nevro sales stabilization and spine product launch execution in early 2027.
Other developments that session
Globus Medical cuts 2026 revenue guidance due to spine launch delays and Nevro sales weakness.
Frequently asked questions
Why did Globus Medical, Inc. (GMED) stock fall on Nov 6, 2026?
Globus Medical reported Q3 2026 net sales of $763.7 million, missing consensus estimates (~$792–$793 million) and declining 0.7% year-over-year, while management cut full-year 2026 revenue guidance from $3.18–$3.22 billion to $3.09 billion (investing.com). The selloff was compounded by a 25.7% drop in Nevro sales, slower sales rep productivity, and delayed spine product launches now pushed to 2027, plus BMO Capital Markets downgrading GMED from Outperform to Market Perform with a price target cut from $94 to $78. Stock fell 11.15% to $72.36 on elevated volume of 5.1 million shares (6.08x historical average for this time of session).
How much did GMED stock fall on Nov 6, 2026?
GMED fell 12.8% during the Nov 6, 2026 trading session.
